Elixiron Immunotherapeutics (Taiwan)

Elixiron Immunotherapeutics (Taiwan) is a biotechnology company headquartered in Taipei, Taiwan, focused on immunotherapeutics — the discovery and development of therapies that harness or modulate the immune system, including antibody-based medicines. The company is registered and operates from Taipei, positioning it within Taiwan's growing biotech and biopharmaceutical sector, which has become a regional hub for antibody engineering, immuno-oncology and specialty therapeutics. As an immunotherapeutics specialist, Elixiron's work sits at the intersection of immunology and drug development. Companies in this space typically pursue monoclonal antibodies, bispecific or engineered antibody formats, and immune-modulating biologics aimed at cancer, autoimmune and inflammatory diseases. Elixiron's public-facing presence is anchored by its corporate website, elixiron.com, which serves as the primary channel for company information. The company is privately held and does not appear on a public stock exchange, so detailed financial disclosures, pipeline data and partnership announcements are not broadly available in public sources. Its identity in public records is limited to its status as a Taipei-based company in the immunotherapeutics field. Because verifiable public information is sparse, this dossier reflects only what can be confirmed: the company's name, its Taipei headquarters, its Taiwan country of operation, and its focus on immunotherapeutics. Additional details such as founding year, founders, ownership structure, specific drug candidates and clinical milestones should be treated as unverified until supported by primary sources.

Elixiron Immunotherapeutics (Taiwan) is a biotechnology company based in Taipei, Taiwan, operating in the immunotherapeutics segment of the life sciences industry. Public records identify it as a company in Taipei, Taiwan, and its corporate website (elixiron.com) serves as its primary public information channel. The company's name and focus indicate a specialization in immunotherapeutics — therapies designed to modulate the immune system, a category that includes antibody-based biologics and related immune-modulating treatments. Taiwan has developed a substantial biotech ecosystem, with Taipei and surrounding science parks hosting contract research organizations, antibody discovery firms and specialty pharma developers. Elixiron sits within this ecosystem as a Taipei-headquartered immunotherapeutics developer. Because the company is privately held and public disclosures are limited, a detailed corporate history — including founding date, founding team, financing rounds, pipeline progression and partnerships — cannot be reconstructed from the available evidence. What is verifiable is its identity as a Taipei, Taiwan company in the immunotherapeutics field. Any further historical detail would require primary sources such as company filings, press releases or regulatory registrations.

Immunotherapeutics-focused biotechnology company based in Taipei, Taiwan.

• 2021.02.09

  Reported2021.02.10

  4B Technologies and Elixiron enter exclusive licensing partnership[3]福贝生物与Elixiron达成独家授权合作finance.sina.com.cn

  4B Technologies (福贝生物) and Elixiron Immunotherapeutics entered an exclusive licensing partnership to jointly advance development, production, and commercialization of CSF1R inhibitor EI-1071 in areas including neurological diseases.

• 2020.08.25

  Reported2020.08.25

  Elixiron receives $1 million research grant[4]安立玺荣获得100万美元研发奖助tech.sina.com.cn

  Elixiron Immunotherapeutics announced that it received a $1 million grant through the 2020 Part The Cloud-Gates Partnership program to advance its EI1071 drug toward a Phase I human clinical trial.

Read more

1. 1Elixiron Immunotherapeutics (Taiwan) — Wikidatawikidata.org
2. 2Elixiron Immunotherapeutics official websiteelixiron.com
3. 3福贝生物与Elixiron达成独家授权合作finance.sina.com.cn
4. 4安立玺荣获得100万美元研发奖助tech.sina.com.cn